ClinicalTrials.gg

Program

IDP-126

A development code. Also written as “IDP-126 Gel”, “CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.” and “IDP-126 Component A”.

Its studies are mostly in Acne Vulgaris, led by Bausch Health Companies.

Furthest: phase 4, since Feb 5, 20266 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies61 open or runningphase 4since Feb 5, 2026May 26, 2017Dec 2027phase 4 · NCT07524946

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2017First study: phase 2 study in Acne VulgarisFirst studyNCT03170388 · 741 enrolled · United States, Canada
  2. Aug 20, 2018Phase 1 study in Acne VulgarisNCT03653403 · 61 enrolled · United States
  3. Dec 30, 20192 phase 3 studies in Acne VulgarisNCT04214652, NCT04214639
  4. May 14, 2021Phase 2 study in Acne VulgarisNCT04892706 · 686 enrolled · United States, Belgium, Canada
  5. Feb 5, 2026Phase 4 study in Acne VulgarisNCT07524946 · 100 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 4 study in Acne VulgarisNCT07524946

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07524946Acne Vulgaris · United States4RecruitingDec 2027100
NCT04892706Acne Vulgaris · United States, Belgium, Canada2CompletedSep 28, 2022686
NCT04214652Acne Vulgaris · United States, Canada3CompletedMar 18, 2021180
NCT04214639Acne Vulgaris · United States, Canada3CompletedJan 18, 2021183
NCT03653403Acne Vulgaris · United States1CompletedJun 19, 201961
NCT03170388Acne Vulgaris · United States, Canada2CompletedApr 23, 2019741

How it is read

Names in the registry

  • “IDP-126 Gel”, 5 entries
  • “CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.”, 1 entry
  • “IDP-126 Component A”, 1 entry
  • “IDP-126 Component B”, 1 entry
  • “IDP-126 Component C”, 1 entry

Codes read as this program: IDP126.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.